Renal Cancer References

Last updated: 19 August 2025
  1. Albiges L, Gizzi M, Carton E, et al. Axitinib in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2015 May;15(5):499-507. doi: 10.1586/14737140.2015.1033408. PMID: 25907705
  2. American Cancer Society. Kidney cancer (adult) – renal cell carcinoma overview. ACS. . http://www.cancer.org/acs/groups/cid/documents/webcontent/003052-pdf.pdf. Jan 2015. Accessed 5 Oct 2015.
  3. American Society of Clinical Oncology. Cabozantinib improves upon the standard of care for advanced kidney cancer. ASCO. http://www.asco.org/press-center/cabozantinib-improves-upon-standard-care-advanced-kidney-cancer. Jan 2016.
  4. American Urological Association. Follow-up care for renal cancer. AUA. https://www.auanet.org/education/guidelines/renal-cancer-follow-up.cfm. Apr 2013.
  5. Atkins M. Clinical manifestations, evaluation, and staging of renal cell carcinoma. UpToDate. http://www.uptodate.com/. 16 Jul 2020. Accessed 5 Oct 2015.
  6. Atkins M, Choueiri T. Epidemiology, pathology, and pathogenesis of renal cell carcinoma. UpToDate. http://www.uptodate.com/contents/epidemiology-pathology-and-pathogenesis-of-renal-cell-carcinoma. Mar 2015. Accessed 5 Oct 2015.
  7. Atkins MB. Overview of the treatment of renal cell carcinoma. UpToDate. http://www.uptodate.com/. 02 Apr 2025. Accessed 5 Oct 2015.
  8. Bracarda S, Hutson TE, Porta C, et al. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br J Cancer. 2012 Apr;106(9):1475-1480. doi: 10.1038/bjc.2012.89. PMID: 22441644
  9. Cancer Therapy Advisor. Renal cell carcinoma treatment regimens. http://www.cancertherapyadvisor.com/bladder,-kidney,-and-other-urologic-cancers/category/152/0/.
  10. Cancer Treatment Centers of America. Kidney cancer types. http://www.cancercenter.com/kidney-cancer/types.
  11. Canfield S, Dabestani S, Hofman F, et al. European Association of Urology. Guidelines on renal carcinoma. EAU. http://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma_LR1.pdf. Mar 2015.
  12. Chemocare. Nivolumab. http://www.chemocare.com/chemotherapy/drug-info/Nivolumab.aspx.
  13. Cohen R. Pathology of clear cell carcinoma. eMedicine. http://emedicine.medscape.com/article/1612043-overview#a5. Feb 2014. Accessed 5 Oct 2015.
  14. da Silva RD, Gustafson D, Nogeira L, et al. Targeted therapy for metastatic renal carcinoma: an update. Journal of Kidney Cancer and VHL. 2014;1(6):63-73. doi: 10.15586/jkcvhl.2014.14.
  15. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2014 Sep;25(Suppl 3):iii49–iii56. doi: 10.1093/annonc/mdu259. Accessed 5 Oct 2015. PMID: 25210086
  16. European Association of Urology. Guidelines on renal cell carcinoma (2015). EAU. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Renal-Cell-Cancer-2015-v2.pdf.
  17. Johnson M. Renal cancer: Symptoms, diagnosis, pathology & prognosis. http://www.baun.co.uk/conference/pdfs/Friday/Johnson.pdf.
  18. Kidney Health Australia. Kidney cancer. http://www.kidney.org.au/KidneyCancer/tabid/799/Default.aspx. Accessed 5 Oct 2015.
  19. Kidney Cancer Canada. Types of kidney cancer and related syndromes. http://www.kidneycancercanada.ca/for-patients-and-caregivers/types-of-kidney-cancer-and-related-symptoms.
  20. Larkin J, Mayer F, Wood L, et al. Axitinib for the treatment of metastatic renal cell carcinoma: Recommendations for therapy management to optimize outcomes. Am J Clin Oncol. 2014 Aug;37(4):397-403. doi: 10.1097/COC.0b013e31827b45f9. Accessed 6 Jan 2016. PMID: 23357974
  21. Lawrence L. METEOR: Cabozantinib improves survival in advanced kidney cancer. http://www.cancernetwork.com/ecc-2015/meteor-cabozantinib-improves-survival-advanced-kidney-cancer. Sep 2015. Accessed 13 Jan 2016.
  22. Lee CH, Hotker A, Voss M, et al. Bevacizumab monotherapy as salvage therapy for advanced clear cell renal cell carcinoma pretreated with targeted drugs. Clin Genitourin Cancer. 2016 Feb;14(1):56-62. doi: 10.1016/j.clgc.2015.07.010. PMID: 26404107
  23. Madell R. 5 Types of renal carcinoma: What you need to know. Healthline. http://www.healthline.com/health-slideshow/types-renal-cell-carcinoma#1. Feb 2014. Accessed 5 Oct 2015.
  24. Motzer R, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2015: Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015 Feb;13(2):151-159. PMID: 25691606
  25. Motzer RJ, Alyasova A, Karpenko A, et al. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4) [Abstract]. Ann Oncol. 2016 Mar;27(3):441-448 . doi: 10.1093/annonc/mdv612. PMID: 26681676
  26. Muglia V, Adison P. Renal cell carcinoma: Histological classification and correlation with imaging findings. Radiol Bras. 2015 May-Jun;48(3):166-174. doi: 10.1590/0100-3984.2013.1927. Accessed 5 Oct 2015
  27. National Cancer Institute. General information about renal cancer. NIH. http://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq. Jul 2015.
  28. National Cancer Institute. Nivolumab. NIH. http://www.cancer.gov/about-cancer/treatment/drugs/nivolumab.
  29. National Cancer Institute. Kidney cancer – for health professionals. NIC. http://www.cancer.gov/types/kidney/hp.
  30. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 2.2014. NCCN. http://www.tri-kobe.org/nccn/guideline/urological/english/kidney.pdf. Dec 2013.
  31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 2.2016. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Nov 2015.
  32. North S, Basappa N, Canil C, et al. Management of advance kidney cancer: Canadian kidney cancer forum consensus update. CUAJ. 2015 May-Jun;9(5-6):164-170. http://www.kidneycancercanada.ca/media/954412/2894-10790-1-pb.pdf.
  33. Reaume MN, Graham G, Tomiak E, eta al. Canadian guideline on genetic screening for hereditary renal cancers. CUAJ. 2013 Sep-Oct;7(9-10):319-323.
  34. Rendon R, Kapoor A, Breau R, et al. Surgical management of renal cell carcinoma: Canadian kidney cancer forum consensus. CUAJ. 2014 May-Jun;8(5-6):E398-E412. Accessed 5 Oct 2015
  35. Results from Phase 2 Trial Investigating Lenvatinib in Metastatic Renal Cell Carcinoma Published in The Lancet Oncology. http://www.prnewswire.com/news-releases/results-from-phase-2-trial-investigating-lenvatinib-in-metastatic-renal-cell-carcinoma-published-in-the-lancet-oncology-300160976.html.
  36. Sachdeva K. Renal cell carcinoma clinical presentation: history, physical examination, staging. eMedicine. http://emedicine.medscape.com/article/281340-overview. Sep 2015. Accessed 5 Oct 2015.
  37. Sachdeva K. Renal cell carcinoma workup. eMedicine. http://emedicine.medscape.com/article/281340-workup#showall. Dec 2015.
  38. Schmidinger M, Larkin J, Porta C. Evidence and experience for the management of metastatic renal cell carcinoma. EJC Supplements. 2013:001-8. doi: 10.1016/j.ejcsup.2013.07.001.
  39. Society of Interventional Radiology. Interventional radiology treatments for kidney cancer. SIR. http://www.sirweb.org/patients/kidney-cancer. 2015. Accessed 5 Oct 2015.
  40. Stephenson R. Guidelines for the management of urological cancer. Kidney cancer treatment guidelines. http://www.mccn.nhs.uk/userfiles/documents/Renal%20Cancer%20Guidelines.pdf. Aug 2012.
  41. Urology at UCLA. Kidney cancer symptoms, treatment and diagnosis. UCLA. http://urology.ucla.edu/body.cfm?id=136.
  42. Weil Cornell Medical College, James Buchanan Brady Foundation, Department of Urology. Kidney cancer/general information. https://www.cornellurology.com/clinical-conditions/kidney-cancer/kidney-cancer-whats-new/. Accessed 5 Oct 2015.
  43. White V. Eisai submits MAA for Lenvatinib in renal cell carcinoma. europeanpharmaceuticalreview. http://www.europeanpharmaceuticalreview.com/37765/news/industry-news/eisai-submits-maa-lenvatinib-renal-cell-carcinoma/. Jan 2016. Accessed 13 Jan 2016.
  44. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 May;30(5):706-720. doi:10.1093/annonc/mdz056. PMID: 30788497
  45. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer. Version 2.2020. NCCN. https://www.nccn.org/. 5 Aug 2019.
  46. Atkins MB. Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma. UpToDate. https://www.uptodate.com. 20 Jan 2021.
  47. Choueiri TK. The treatment of advanced non-clear cell renal cell carcinoma. UpToDate. https://www.uptodate.com. 14 Jan 2021.
  48. Curigliano G, on behalf of the ESMO Guidelines Committee. Recent eUpdate on Cabozantinib and Nivolumab for first-line clear cell renal cancer to the ESMO clinical practice guidelines on renal cell carcinoma. Ann Oncol. 2020 Nov.
  49. ESMO Guidelines Committee. eUpdate – renal cell carcinoma algorithm. ESMO. https://www.esmo.org/. 07 Feb 2020.
  50. ESMO Guidelines Committee. eUpdate – renal cell carcinoma treatment recommendations. ESMO. https://www.esmo.org/. 07 Feb 2021.
  51. George D, Jonasch E. Systemic therapy of advanced renal cell carcinoma. UpToDate. https://www.uptodate.com. 18 Nov 2020.
  52. Hines A, Goldberg SN. Radiofrequency ablation and cryoablation for renal cell carcinoma. UpToDate. https://www.uptodate.com. 23 Apr 2020.
  53. Ljungberg B, Albiges L, Bensalah K, et al. EAU guidelines on renal cell carcinoma. EAU. https://www.uroweb.org/. Mar 2020.
  54. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer. Version 1.2021. NCCN. https://www.nccn.org/. 15 Jul 2020.
  55. Richie JP. Definitive surgical management of renal cell carcinoma. UpToDate. https://www.uptodate.com. 17 Sep 2020.
  56. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer. Version 1.2022. NCCN. https://www.nccn.org/. 01 Jul 2021.
  57. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. 2015 Nov;16(15):1473-1482. doi: 10.1016/S1470-2045(15)00290-9. PMID: 26482279
  58. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer. Version 2.2023. NCCN. https://www.nccn.org/. Aug 2022.
  59. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer. Version 3.2023. NCCN. https://www.nccn.org/. Sep 2022.
  60. Powles T, Albiges L, Bex A, et al; ESMO Guidelines Committee. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021 Dec;32(12):1511-1519. doi: 10.1016/j.annonc.2021.09.014. PMID: 34597799
  61. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer. Version 1.2024. NCCN. https://www.nccn.org/. Jun 21 2023.
  62. Atkins MB. Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma. UpToDate. https://www.uptodate.com/. 02 Apr 2025.
  63. Bex A, Albiges L, Bedke J, et al. EAU guidelines on renal cell carcinoma. European Association of Urology. https://www.uroweb.org/. 2025.
  64. Choueiri TK, Pal SK. The treatment of advanced and metastatic non-clear cell renal cell carcinoma. UpToDate. https://www.uptodate.com. 29 Jan 2025.
  65. George D, Jonasch E. Systemic therapy for advanced and metastatic clear cell renal cell carcinoma. UpToDate. https://www.uptodate.com/. 27 Mar 2025.
  66. Richie JP. Definitive surgical management of renal cell carcinoma. UpToDate. https://www.uptodate.com/. 02 Apr 2024.
  67. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): kidney cancer. Version 3.2025. NCCN. https://www.nccn.org/. 09 Jan 2025.